Symptoms & Diagnosis of Primary Myelofibrosis

Primary Myelofibrosis (PMF) is a complex blood cancer that often takes time to diagnose because its symptoms can mirror other conditions. It is defined by the development of scar tissue in the bone marrow, which interferes with the body’s ability to produce healthy blood cells ^[1]. Understanding the specific criteria doctors use to identify PMF can help you participate more actively in your care.

Common Signs and Symptoms

While some people are diagnosed during routine blood work without any symptoms, many experience “constitutional symptoms”—signals from the body that something is wrong ^[2]. Common presentations include:

• Severe Fatigue: The most common symptom, often linked to anemia (low red blood cell counts) ^[3][4].
• Splenomegaly: An enlarged spleen, which may cause a feeling of fullness in the upper left abdomen or pain ^[4][2].
• Night Sweats and Weight Loss: These are caused by the body’s inflammatory response to the disease ^[2][4].
• Bone Pain: Often felt as a deep, aching sensation ^[5].
• Abnormal Blood Counts: This can include very high or very low levels of white blood cells and platelets ^[6].

A Clinicopathologic Diagnosis

While blood tests and genetic markers are important, the diagnosis of PMF is a “clinicopathologic” one—meaning it requires an integrated assessment of the bone marrow biopsy, clinical findings, and exclusion of other myeloid diseases like Chronic Myeloid Leukemia (CML) ^[7]. A hematopathologist examines a sample of your bone marrow under a microscope to look for key features:

1. Megakaryocyte Atypia: Abnormalities in the size, shape, and clustering of the cells that make platelets ^[8].
2. Marrow Cellularity: Changes in how crowded the bone marrow is.
3. Fibrosis Grading: The amount of scarring in the marrow, measured on a scale from MF-0 (no scarring) to MF-3 (severe scarring) ^[9][10].

Pre-Fibrotic vs. Overt Myelofibrosis

Doctors divide PMF into two stages based on the combination of biopsy results and clinical criteria:

• Pre-fibrotic PMF (Pre-PMF): In this early stage, the marrow shows abnormal cell growth and characteristic cellularity with minimal scarring (grade MF-0 or MF-1), alongside specific clinical criteria ^[6]. Patients may have high platelet counts, often mimicking another condition called Essential Thrombocythemia ^[11].
• Overt Fibrotic PMF: This stage is defined by significant scarring (grade MF-2 or MF-3) and the appropriate clinical findings ^[8]. It is more likely to cause significant spleen enlargement and a characteristic finding in the blood called leukoerythroblastosis. This is a blood-film pattern where immature red and white blood cells appear because the marrow architecture is disrupted and blood production has moved outside the marrow ^[6][12].

Primary vs. Secondary Myelofibrosis

It is important to distinguish between “primary” and “secondary” forms of the disease:

• Primary Myelofibrosis (PMF): The disease starts as myelofibrosis from the beginning ^[13].
• Secondary Myelofibrosis: This occurs when a patient who was previously diagnosed with Polycythemia Vera (PV) or Essential Thrombocythemia (ET) sees their condition evolve into myelofibrosis ^[14]. This is often called “post-PV MF” or “post-ET MF” ^[15].

The Role of Genetics

Testing for “driver mutations” in the JAK2, CALR, or MPL genes is a key part of the diagnostic process ^[16]. About 90% of PMF patients carry one of these mutations ^[17].

However, finding a mutation is supportive, not definitive, as they also appear in other blood cancers ^[8]. Conversely, about 10% of patients are “triple-negative,” meaning they have none of these three mutations but still have PMF based on their biopsy and clinical symptoms ^[17][3]. In these cases, doctors look for other genetic clues or specific biopsy features to confirm the diagnosis ^[18]. Ultimately, the diagnosis requires bringing all pathology, molecular testing, and clinical evidence together ^[7].